Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 3,236 matching trials from the live ClinicalTrials.gov search.

Filters: Not yet recruiting Clear all

Conditions: Heart Failure With Reduced Ejection Fraction, Cognitive Impairment, Mild, Neuroinflammation, Vascular Contributions to Cognitive Impairment and Dementia (VCID)
Interventions: [11C]PS13: [carbon-11]PS13; COX-1 PET radioligand, Sacubitril-Valsartan; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 50 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Cubital Tunnel Syndrome
Interventions: Cubital tunnel release, Conservative Arm; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 7
States / cities: Bethel Park, Pennsylvania • Cranberry Township, Pennsylvania • Monroeville, Pennsylvania + 1 more

Conditions: Chalazion
Interventions: Sham IPL, Active IPL; Device
Lead sponsor: Lumenis Be Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: New York, New York • Seattle, Washington

Conditions: Carbon Monoxide Poisoning, Carbon Monoxide Intoxication, Carbon Monoxide Encephalopathy, Carbon Monoxide-induced Parkinsonism
Interventions: saline placebo, Dexamethasone; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Inflammatory Bowel Disease
Interventions: elemental diet (ED); Dietary Supplement
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Sensorineural Hearing Loss, Bilateral Hearing Loss, Cochlear Implantation, Hearing Disorders, Hearing Disorders and Deafness, Inner Ear Disorders, Hearing Impairment
Interventions: IotaSoft Robotic Insertion System, Manual Cochlear Implant Insertion; Device · Procedure
Lead sponsor: AdventHealth; Other
Eligibility: 18 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Kissimmee, Florida

Conditions: Hypertension
Interventions: Self-Titration; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 35 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Somerville, Massachusetts

Conditions: Stress Disorders, Post-Traumatic, Substance-Related Disorders
Interventions: Written Exposure Therapy, Cognitive Behavioral Therapy for Substance Use Disorders (skill components), Cognitive Behavioral Therapy for Substance Use Disorders; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2028 – 2030
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Interventions: Nemtabrutinib; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Familial Hypercholesterolemia
Interventions: Cascade Screening; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Dysphagia, Critical Illness
Interventions: Expiratory muscle strength training (EMST), Standard of Care Dysphagia Treatment, Intensive Dysphagia Treatment; Device · Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Lupus Nephritis
Interventions: BMS-986553; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 11
States / cities: Newport Beach, California • Worcester, Massachusetts • Ann Arbor, Michigan + 7 more

Conditions: Alcohol Use Disorder
Interventions: Nimodipine, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteers
Interventions: Formulation A, Formulation B, Formulation C; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Sepsis, Septic Shock, Sepsis-Associated Immune Dysregulation
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2037
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Cardiovascular Diseases, Insulin Sensitivity/Resistance, Metabolic Disease, Metabolism, Energy Expenditure, Obesity
Interventions: Vericiguat 10 MG, Placebo, Insulin Sensitivity Test, Resting Energy and Exercise Energy Expenditure Assessment, White Adipose Tissue Biopsy, MRI-PET Scan for Brown Adipose Tissue Volume Assessment; Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Peripheral Artery Disease (PAD), Intermittent Claudication
Interventions: Therapeutic calf stretching, Sham calf stretching; Behavioral
Lead sponsor: Penn State University; Other
Eligibility: 50 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 2
States / cities: Manhattan, Kansas • Hershey, Pennsylvania

Conditions: Waldenstrom Macroglobulinemia
Interventions: epcoritamab; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Health-Related Quality-of-Life, Cancer, Health Communication
Interventions: ReSPECT; Behavioral
Lead sponsor: Connecticut Children's Medical Center; Other
Eligibility: 15 Years to 25 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Major Depressive Disorder
Interventions: Cognitive Behavioral Therapy (CBT), Whole-Body Hyperthermia; Behavioral · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: San Francisco, California • Boston, Massachusetts • Cleveland, Ohio

Conditions: Lung Cancer
Interventions: Text Messages (TM+), Chatbot (CA), Video (VID), Reactive Patient Navigation (RPN), Proactive Patient Navigation (PPN); Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 50 Years to 80 Years
Enrollment: 18,894 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma
Interventions: Ivonescimab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Persons With Psychiatric Disorders
Interventions: Perinatal peer support; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2028 – 2030
U.S. locations: 1
States / cities: West Los Angeles, California

Conditions: Math Learning Disability, Learning Disabilities, Learning Disabilities, Child, Dyscalculia, Child Development
Interventions: Speeded practice training, Arithmetic strategy training; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 6 Years to 12 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Palo Alto, California

Search by objective public record fields.

[11C]PS13 PET Imaging of Neuroinflammation in Heart Failure With Reduced Ejection Fraction

Comparing Surgical and Nonsurgical Outcomes of Cubital Tunnel Syndrome

Evaluation of Effectiveness and Safety of Intense Pulsed Light Treatment for Chalazion

Carbon Monoxide Hyperbaric Oxygen With Steroid Therapy

The EDICT Trial - Therapy for Inflammatory Bowel Disease Flares

Comparative Analysis of Hearing Outcomes: Robotic vs. Manual Insertion of Cochlear Implants

Antihypertensive Self-titration in US Primary Care

RISE for PTSD and Substance Use Disorder in Veterans

Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor

Penn Family Screening for Familial Hypercholesterolemia (NHLBI R33) Trial 3

Optimizing Dysphagia Treatment Delivery in Acute Care: A Hybrid Efficacy Implementation Trial

A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases

Effects of Nimodipine on Alcohol Drinking

Sustained Release Oral Formulation For Treatment Of Parkinsons Disease

Immune Dysregulation During Sepsis: A Natural History Cohort

VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway

Daily Stretching to Improve Walking in Older Patients With Peripheral Artery Disease: The STRETCH PAD Study

Epcoritamab as Consolidative Therapy for Waldenstr(SqrRoot)(Delta)m Macroglobulinemia (WM) Treated With a Bruton Tyrosine Kinase Inhibitor (BTKi)

Improving Sexual and Reproductive Health Communication for Adolescent and Young Adult Oncology Patients

Multi-site Feasibility of an Integrated Treatment for the Biology and Experience of Depression: The MULTIBED Study

Population Health Management -Increase Lung Cancer Screening in Community Health Centers (LungSMART)

STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)

Perinatal Peer Support for Veterans With Serious Mental Illness

Intervention on Mathematical Problem-Solving Skills